XBiotech (XBIT) Competitors $3.20 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.04 (+1.25%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIT vs. VIGL, NBTX, OLMA, FULC, ABEO, CAPR, ZYBT, ADCT, BNTC, and FDMTShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Vigil Neuroscience (VIGL), Nanobiotix (NBTX), Olema Pharmaceuticals (OLMA), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Its Competitors Vigil Neuroscience Nanobiotix Olema Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Capricor Therapeutics Zhengye Biotechnology ADC Therapeutics Benitec Biopharma 4D Molecular Therapeutics XBiotech (NASDAQ:XBIT) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk. Do institutionals & insiders have more ownership in XBIT or VIGL? 55.7% of XBiotech shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 18.0% of Vigil Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, XBIT or VIGL? Vigil Neuroscience is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotechN/AN/A-$38.53M-$0.92-3.48Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.93 Which has more risk & volatility, XBIT or VIGL? XBiotech has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.33, meaning that its share price is 233% more volatile than the S&P 500. Is XBIT or VIGL more profitable? XBiotech's return on equity of -15.60% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -15.60% -14.64% Vigil Neuroscience N/A -111.70%-74.67% Do analysts recommend XBIT or VIGL? Vigil Neuroscience has a consensus target price of $10.80, indicating a potential upside of 34.16%. Given Vigil Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Vigil Neuroscience is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vigil Neuroscience 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer XBIT or VIGL? In the previous week, XBiotech had 2 more articles in the media than Vigil Neuroscience. MarketBeat recorded 2 mentions for XBiotech and 0 mentions for Vigil Neuroscience. XBiotech's average media sentiment score of 1.07 beat Vigil Neuroscience's score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Overall Sentiment XBiotech Positive Vigil Neuroscience Neutral SummaryXBiotech beats Vigil Neuroscience on 8 of the 12 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.56M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-3.4821.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book0.568.079.116.39Net Income-$38.53M-$54.72M$3.26B$265.66M7 Day Performance1.59%2.62%2.11%1.98%1 Month Performance3.90%7.63%5.12%1.33%1 Year Performance-47.71%13.11%31.25%21.15% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech1.7446 of 5 stars$3.20flatN/A-51.3%$97.56MN/A-3.48100News CoveragePositive NewsVIGLVigil Neuroscience1.9236 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340Positive NewsNBTXNanobiotix0.7946 of 5 stars$8.80+11.3%$8.00-9.1%+105.1%$379.23M$39.18M0.00100News CoverageGap UpOLMAOlema Pharmaceuticals1.8257 of 5 stars$5.76+4.5%$24.00+316.7%-55.3%$378.17MN/A-2.9170FULCFulcrum Therapeutics0.9478 of 5 stars$6.64-2.6%$7.57+14.0%-31.7%$368.90M$80M-5.44100ABEOAbeona Therapeutics4.4544 of 5 stars$6.91-3.1%$19.50+182.2%+35.7%$364.75M$400K9.8790News CoverageAnalyst RevisionCAPRCapricor Therapeutics3.1121 of 5 stars$7.70-3.3%$22.56+192.9%+53.1%$363.91M$13.39M-4.70101Trending NewsZYBTZhengye BiotechnologyN/A$7.84+4.4%N/AN/A$354.22M$25.53M0.00278News CoverageGap DownADCTADC Therapeutics2.0554 of 5 stars$3.24+3.5%$7.75+139.2%+5.4%$352.12M$70.84M-2.06310High Trading VolumeBNTCBenitec Biopharma1.4454 of 5 stars$12.71-2.3%$26.00+104.6%+41.7%$341.51MN/A-8.4220News CoverageFDMT4D Molecular Therapeutics2.1396 of 5 stars$7.27+0.1%$30.40+318.2%-54.9%$339.06M$40K-2.06120 Related Companies and Tools Related Companies VIGL Competitors NBTX Competitors OLMA Competitors FULC Competitors ABEO Competitors CAPR Competitors ZYBT Competitors ADCT Competitors BNTC Competitors FDMT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access